Alnylam Pharmaceuticals, Inc. (ALNY) Key Metrics

NASDAQ: ALNYValuation, returns, debt and efficiency ratios over 10 years.

ALNY valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$31.02B
Enterprise value
$30.94B
P/E (TTM)
39.1
Forward P/E
19.7
PEG ratio
0.32
Price / sales
6.5
10-yr median 29.1
Price / book
24.9
10-yr median 11.7
EV / EBITDA
28.6
Dividend yield
—
Beta
0.27

ALNY key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

ALNY valuation Price multiples at each fiscal year-end price.

Price / sales+7.9%
14.4
2025 · hover or tap a bar for each year
2016: 68.0 (−64.7%)2017: 128.0 (+88.3%)2018: 97.9 (−23.5%)2019: 57.3 (−41.5%)2020: 30.3 (−47.0%)2021: 23.8 (−21.5%)2022: 27.9 (+17.2%)2023: 13.1 (−53.1%)2024: 13.4 (+2.2%)2025: 14.4 (+7.9%)
20162025
Price / book−84.8%
67.9
2025 · hover or tap a bar for each year
2016: 3.5 (−44.3%)2017: 6.5 (+87.0%)2018: 5.6 (−13.5%)2019: 8.7 (+55.3%)2020: 14.7 (+68.1%)2021: 34.1 (+132.2%)2024: 447.72025: 67.9 (−84.8%)
20162025
Price / free cash flow
115.1
2025 · hover or tap a bar for each year
2023: 570.02025: 115.1
20162025
Free cash flow yield+1.0 pts
0.9%
2025 · hover or tap a bar for each year
2016: −11.6% (−9.1 pts)2017: −4.2% (+7.4 pts)2018: −9.4% (−5.2 pts)2019: −3.3% (+6.1 pts)2020: −4.6% (−1.3 pts)2021: −3.6% (+1.0 pts)2022: −2.1% (+1.5 pts)2023: 0.2% (+2.3 pts)2024: −0.1% (−0.3 pts)2025: 0.9% (+1.0 pts)
20162025

ALNY valuation history

Fiscal year-endToday10-year median

ALNY returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

ALNY debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

ALNY cash returned to shareholders

DividendsBuybacksFree cash flow

ALNY price vs earnings per share

Share price at year-endEPS (right axis)

ALNY key metrics

2016–2025
Alnylam Pharmaceuticals, Inc. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$53.56B$30.04B$23.91B$28.92B$20.09B$14.94B$12.58B$7.33B$11.50B$3.20B
Enterprise value$51.93B$28.64B$22.77B$28.05B$18.65B$13.59B$11.35B$6.34B$9.84B$2.42B
P/E ratio170.7—————————
Price / sales14.413.413.127.923.830.357.397.9128.068.0
Price / book67.9447.7——34.114.78.75.66.53.5
Price / free cash flow115.1—570.0———————
Price / operating cash flow102.2—229.5———————
EV / sales14.012.712.527.022.127.651.784.7109.551.4
EV / EBITDA82.2—————————
EV / free cash flow111.6—543.0———————
Earnings yield0.6%−0.9%−1.8%−3.9%−4.2%−5.7%−7.0%−10.4%−4.3%−12.8%
Free cash flow yield0.9%−0.1%0.2%−2.1%−3.6%−4.6%−3.3%−9.4%−4.2%−11.6%
Dividend yield————————0.0%0.0%
Shareholder yield (dividends + buybacks)———0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Share price at fiscal year-end$397.65$235.31$191.41$237.65$169.58$129.97$115.17$72.91$127.05$37.44
Per share
Revenue per share$27.58$17.61$14.64$8.53$7.13$4.29$2.01$0.74$0.99$0.55
Earnings per share$2.33−$2.18−$3.52−$9.30−$7.20−$7.46−$8.11−$7.57−$5.42−$4.79
Operating cash flow per share$3.89−$0.07$0.83−$4.45−$5.42−$5.35−$2.55−$5.59−$4.23−$3.59
Free cash flow per share$3.46−$0.33$0.34−$5.04−$6.06−$5.96−$3.83−$6.85−$5.38−$4.35
Cash per share$21.59$21.11$19.53$18.02$20.56$16.30$14.06$10.77$18.82$11.01
Book value per share$5.86$0.53−$1.77−$1.30$4.97$8.84$13.17$12.94$19.51$10.75
Tangible book value per share$1.45$0.53−$7.35−$3.47$4.97$8.84$13.17$12.94$19.51$10.75
Dividends per share————————$0.00$0.00
Capex per share$0.44$0.27$0.50$0.59$0.64$0.61$1.28$1.26$1.15$0.75
Debt per share$9.49$10.15$10.45$10.85$8.42$4.53$2.78$0.92$0.45$1.89
Shares outstanding134.7M127.7M124.9M121.7M118.5M115.0M109.3M100.6M90.6M85.6M
Change in shares outstanding+5.5%+2.2%+2.6%+2.7%+3.0%+5.2%+8.6%+11.1%+5.8%+1.9%
Returns & profitability
Return on equity (ROE)73.3%———−106.3%−69.9%−64.7%−49.6%−36.5%−37.5%
Return on invested capital (ROIC)——————−286.4%−310.3%−326.5%−203.3%
Return on assets (ROA)6.8%−6.9%−11.9%−31.5%−24.2%−29.6%−44.6%−42.7%−30.1%−31.0%
Return on tangible assets7.2%−6.6%−14.1%−34.5%−23.4%−25.2%−37.0%−48.4%−24.6%−32.5%
Free cash flow margin12.5%−1.9%2.3%−59.1%−85.0%−139.1%−190.5%−920.5%−541.6%−789.4%
Income quality (OCF / net income)1.67—————————
Financial health
Total debt$1.28B$1.30B$1.31B$1.32B$997.6M$521.2M$303.8M$92.9M$41.0M$161.5M
Cash & short-term investments$2.91B$2.69B$2.44B$2.19B$2.44B$1.87B$1.54B$1.08B$1.70B$942.6M
Net debt−$1.63B−$1.40B−$1.13B−$872.2M−$1.44B−$1.35B−$1.23B−$990.1M−$1.66B−$781.1M
Debt / equity1.6219.32——1.700.510.210.070.020.18
Debt / assets0.260.310.340.370.270.150.130.060.020.13
Net debt / EBITDA−2.58—————————
Current ratio2.762.783.083.514.044.474.874.988.995.14
Quick ratio2.712.712.993.343.914.344.714.888.995.14
Interest coverage2.0-1.2-2.3-5.0-5.0-9.8-8.7-27.8-40.9-51.1
Working capital$2.58B$2.11B$2.01B$1.92B$2.11B$2.03B$1.36B$966.5M$1.58B$796.7M
Invested capital−$840.9M−$1.33B−$1.35B−$1.03B−$849.8M−$337.0M$206.4M$311.9M$102.9M$139.1M
Tangible asset value$195.5M$67.1M−$918.4M−$422.8M$588.2M$1.02B$1.44B$1.30B$1.77B$920.2M
Net current asset value−$126.5M−$877.6M−$1.07B−$1.01B−$246.5M$224.0M$759.4M$936.5M$1.55B$646.7M
Graham number$17.52—————————
Graham net-net per share−$4.78−$8.89−$10.57−$10.43−$3.61−$0.23$5.86$8.31$16.58$7.21
Capital allocation
Dividends paid————————$0$0
Share buybacks (net)———$0$0$0$0$3.5M$257,000$596,000
Capex / revenue1.6%1.5%3.4%6.9%9.0%14.3%63.8%169.4%115.9%136.9%
Capex / operating cash flow11.2%—59.7%———————
Capex / depreciation1.050.601.151.621.610.952.5819.727.804.27
Stock-based compensation / revenue9.4%12.1%12.1%22.2%19.6%28.4%79.6%210.6%103.2%160.2%
R&D / revenue35.7%50.1%54.9%85.1%93.8%132.9%298.1%674.7%434.5%810.9%
SG&A / revenue32.6%43.4%43.5%74.3%73.5%119.4%218.0%510.4%221.7%189.5%
Efficiency
Days sales outstanding58.159.556.576.8173.1239.051.3128.5116.4122.4
Days of inventory on hand43.594.6128.2232.8210.4307.6585.62,437.50.00.0
Days payables outstanding55.081.290.3185.4163.3238.1798.08,918.726.128.1
Cash conversion cycle (days)46.672.994.4124.1220.2308.4-161.2-6,352.690.294.3
Receivables turnover6.286.136.464.752.111.537.112.843.142.98
Payables turnover6.634.494.041.972.241.530.460.0413.9612.97
Inventory turnover8.403.862.851.571.731.190.620.15578,100,000.00462,146,000.00
Asset turnover0.810.560.500.290.240.170.110.040.060.04
Average receivables$591.4M$366.5M$282.9M$218.3M$400.5M$322.7M$30.9M$26.4M$28.7M$15.8M
Average payables$102.1M$72.0M$76.8M$85.8M$62.7M$50.9M$54.8M$44.0M$41.4M$35.6M
Average inventory$80.6M$83.8M$109.1M$107.7M$80.8M$65.8M$40.2M$12.0M$1$1
Intangibles / total assets12.0%0.0%18.2%7.5%0.0%0.0%0.0%0.0%0.0%0.0%

Computed from ALNY's annual financial statements (latest annual report filed February 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

ALNY valuation and financial ratios

At the end of fiscal 2025 (December 31, 2025), Alnylam traded at 170.7 times earnings. Based on the latest twelve months, the trailing P/E is 39.1 and the forward P/E is 19.7. Alnylam earned a return on equity of 73.3% in fiscal 2025. It ended the year with $1.3 billion of debt and $2.9 billion in cash and short-term investments, a net cash position of $1.6 billion. The share count rose 57.3% from 85.6M to 134.7M over 9 years.

See the ALNY income statement, the ALNY chart for price history, or the ALNY stock overview for the latest quote and news.

ALNY key metrics FAQ

What is Alnylam's P/E ratio?

Alnylam's trailing P/E ratio is 39.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 19.7. At the end of fiscal 2025 it was 170.7.

What is Alnylam's EV/EBITDA?

Alnylam's enterprise value was 82.2 times EBITDA at the end of fiscal 2025 (enterprise value $51.9 billion, EBITDA $631.4 million); the current EV/EBITDA is 28.6.

What is Alnylam's return on equity?

Alnylam's return on equity (ROE) was 73.3% in fiscal 2025: net income of $313.7 million on average shareholders' equity of $428.1 million.

How much debt does Alnylam have?

Alnylam had total debt of $1.3 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.62 and more cash than debt.

What is Alnylam's free cash flow yield?

Alnylam generated $465.4 million of free cash flow in fiscal 2025, a free cash flow yield of 0.9% on its market value at year-end ($53.6 billion).

What is Alnylam's current ratio?

Alnylam's current ratio was 2.76 at the end of fiscal 2025: current assets were 2.76 times current liabilities.

Biotechnology key metrics